中資投資美醫健初創PatientsLikeMe在美國政府壓力下賣盤
《CNBC》報道,美國醫健初創PatientsLikeMe在美國特朗普政府壓力下,向美國最大醫療保險商聯合健康(UnitedHealth)賣盤,原因為該初創在2017年融資1億美元時,向騰訊(00700.HK)參與投資的深圳iCarbonX出售大部分股權,遭美國外國投資委員會(CFIUS)調查。
PatientsLikeMe提供網上服務,協助病人尋找類似健康情況的病人。該初創上周三(19日)加入聯合健康的研發團隊,並向客戶表示個人資料不會在未經同意下轉移。
早前有報道指,PatientsLikeMe去年收到CFIUS的有關通知,迫使控股股東iCarbonX出售有關持股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.